- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.11.25 | OnKure Therapeutics GAAP EPS of -$1.09 | 2 | Seeking Alpha | ||
| ONKURE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 06.11.25 | OnKure Therapeutics, Inc.: OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update | 154 | GlobeNewswire (Europe) | -- First patients dosed in triplet expansion arms of the PIKture-01 trial evaluating OKI-219 in combination with fulvestrant and ribociclib, and in combination with trastuzumab and tucatinib in patients... ► Artikel lesen | |
| 06.11.25 | OnKure Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 06.05.25 | OnKure Therapeutics, Inc.: OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights | 296 | GlobeNewswire (Europe) | -- Continued progress in the PIKture-01 trial; on track to report additional data in the second half of 2025, including mature single agent and initial combination data -- Expansion of the Company's... ► Artikel lesen | |
| 10.03.25 | OnKure Therapeutics, Inc.: OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights | 383 | GlobeNewswire (Europe) | - PIKture-01 trial update including additional PK data, mature single agent and initial combination data expected in the second half of 2025; reported encouraging preliminary data in December 2024... ► Artikel lesen |
5 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 23,460 | +0,30 % | Pfizer, Astellas Pharma Share Positive Data From Bladder Cancer Trial | NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) and Astellas Pharma Inc., Friday announced the positive results from the Phase 3 EV-304 clinical trial for PADCEV in combination with Keytruda in... ► Artikel lesen | |
| SANOFI | 81,44 | -0,37 % | Regeneron und Sanofi erhalten Empfehlung für erweiterte Dupixent-Zulassung | DJ Regeneron und Sanofi erhalten Empfehlung für erweiterte Dupixent-Zulassung
Von Colin Kellaher
DOW JONES--Der Ausschuss für Humanarzneimittel (CHMP) der Europäischen Arzneimittel-Agentur... ► Artikel lesen | |
| INNOCAN PHARMA | 4,060 | -6,45 % | Innocan Pharma Corporation: FDA Center for Veterinary Medicine Grants Innocan a Fee Waiver in 2026 for the Third Consecutive Time | HERZLIYA, Israel and CALGARY, AB, Feb. 27, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"),... ► Artikel lesen | |
| ASSEMBLY BIOSCIENCES | 25,300 | +0,40 % | Assembly Biosciences: Top-Favorit 2026 - darum bin ich wieder voll dabei! | Alte Liebe rostet nicht: Nach zwischenzeitlich +412% Kursgewinn im vergangenen Jahr und massiven Gewinnmitnahmen habe ich mich als Ex-Großaktionär erneut in erheblichem Umfang bei Assembly Biosciences... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 57,50 | -1,71 % | Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple Sclerosis | SAN FRANCISCO, Feb. 17, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced an academic research collaboration with the University of California... ► Artikel lesen | |
| UNITED THERAPEUTICS | 446,50 | +4,79 % | United Therapeutics reports positive phase 3 trial for ralinepag | ||
| ROYALTY PHARMA | 39,760 | +1,66 % | Royalty Pharma plc: Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform | NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026. Ken will... ► Artikel lesen | |
| JAGUAR HEALTH | 0,939 | +6,62 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 27.02.2026 | Das Instrument UZ9 CA4577022078 INSPIRATION ENERGY CORP. EQUITY wird cum Kapitalmassnahme gehandelt am 27.02.2026 und ex Kapitalmassnahme am 02.03.2026 The instrument UZ9 CA4577022078 INSPIRATION ENERGY... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 54,26 | -3,55 % | BridgeBio Pharma, Inc.: BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates | $154.2 million in total fourth quarter revenues, net, and $502.1 million in full year revenues, net, primarily comprised of net product revenue of $146.0 million and $362.4 million, respectivelyBridgeBio... ► Artikel lesen | |
| CORBUS PHARMACEUTICALS | 6,900 | -4,83 % | Corbus Pharmaceuticals Holdings, Inc. - 8-K, Current Report | ||
| SOLIGENIX | 1,150 | -2,54 % | Soligenix Gets Positive EMA Opinion For Orphan Drug Status Of SGX945 | ||
| KALA BIO | 0,320 | -1,23 % | KALA BIO, Inc.: KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint | -- Study did not meet primary endpoint of complete healing of PCED at Week 8; secondary endpoints also did not achieve statistical significance -- -- KPI-012 was well-tolerated with no treatment-related... ► Artikel lesen | |
| EVOLUS | 3,640 | 0,00 % | Quant snapshot: Impala Platinum, Turkcell Iletisim lead strong buys as Evolus lag | ||
| NEUROGENE | 20,600 | +3,62 % | Morning Market Movers: Neurogene, Duolingo, Xponential Fitness, Emergent BioSolutions See Big Swings | WASHINGTON (dpa-AFX) - At 6:22 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| ACLARIS THERAPEUTICS | 2,371 | -2,23 % | Aclaris Therapeutics, Inc.: Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | - Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial of Anti-TSLP/IL-4Ra Bispecific Antibody ATI-052 Support Rapid Clinical Advancement; Complete Top Line Results... ► Artikel lesen |
ONKURE THERAPEUTICS INC gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 2,710 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ONKURE THERAPEUTICS INC finden Sie auf Wallstreet Online.